Start-ups with new medical technology on the market are becoming overpriced. Therefore, large and mid-size companies are showing a growing interest for earlier stage MedTech companies through R&D collaboration and licensing deals when looking outside for new R&D. Which strategies are those companies pursuing? Is there a difference of pattern between big and mid-size companies approaches when dealing with early stage investment and assets?
Big size vs mid-size companies: Different ways to deal with early-stage start-ups?
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
- 04:30
- 06:00
- Ilya Kazi, Patent Attorney, MATHYS SQUIRE
- Alp Akonur, Director Technology Strategy, BAXTER HEALTHCARE
- Ron Nitzan, Vice President Quality and Regulatory Affairs, KEYSTONE HEART ISRAEL
- Duko Drijfhout, Investment Manager, UNIIQ
